glp-1 review article receptor agonists and cardiovascular outcome trials: An update The expanding role of GLP-1

Empagliflozin and cardiovascular outcomes in Asian patients with type 2 diabetes and established cardiovascular diseaseresults from EMPA-REG OUTCOME

In addition, weight loss medications are generally not prescribed for patients with eating disorders, and, therefore, patients should be screened for these conditions

Some women may find that even moderate resistance exercise a few times per week makes a noticeable difference in how they feel and function

But weight loss is not fat loss

Always label the vial with the date of reconstitution and the final concentration (e.g., "Retatrutide 10 mg/mL, Reconstituted on [Date]")

In April 2026, Foundayo received FDA approval in the United States